Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 2Interleukin-2 2Biopsy 2montanide ISA 51 1liposomal doxorubicin 1cemiplimab 1cc-486 1brodalumab 1atezolizumab 1SUB1 protein, human 1Radiotherapy, Image-Guided 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Mass Screening 1Injections 1Immunotherapy 1Immunohistochemistry 1IT-101 1Genetic Profile 1Floderm topical cream 1Drug Therapy 1Camptothecin 1CALAA-01 1Biological Therapy 1Azacitidine 12-cyclohexylidenhydrazo-4-phenyl-thiazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × CALAA-01 × Breast × Clear all
NCT00689065 2013-11-01

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Calando Pharmaceuticals

Phase 1 Terminated
24 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡